Aura Financial Statements From 2010 to 2024

AURA Stock  USD 8.96  0.08  0.90%   
Aura Biosciences financial statements provide useful quarterly and yearly information to potential Aura Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aura Biosciences financial statements helps investors assess Aura Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aura Biosciences' valuation are summarized below:
Market Capitalization
443.6 M
Earnings Share
(1.73)
We have found one hundred twenty available fundamental signals for Aura Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Aura Biosciences prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Enterprise Value is expected to grow to about 426.5 M
Check Aura Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aura Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 7.4 M, Depreciation And Amortization of 1 M or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.63. Aura financial statements analysis is a perfect complement when working with Aura Biosciences Valuation or Volatility modules.
  
Check out the analysis of Aura Biosciences Correlation against competitors.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.

Aura Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets153.6 M255.1 M79 M
Slightly volatile
Short and Long Term Debt Total20.5 M19.6 M4.2 M
Slightly volatile
Other Current Liabilities3.6 M5.2 M3.6 M
Pretty Stable
Total Current Liabilities8.6 M12.4 M6.9 M
Slightly volatile
Other Liabilities68.8 K74.7 K89.3 K
Slightly volatile
Property Plant And Equipment Net13.5 M22 M7.2 M
Slightly volatile
Accounts Payable2.2 M1.8 M2.2 M
Pretty Stable
Cash79.5 M41.1 M48.9 M
Slightly volatile
Non Current Assets Total14.1 M23.3 M7.4 M
Slightly volatile
Non Currrent Assets Other1.3 M1.3 M266.1 K
Slightly volatile
Other Assets0.951.0142.7 K
Pretty Stable
Long Term Debt39.2 K44.1 K48 K
Slightly volatile
Cash And Short Term Investments135.1 M226.2 M69.4 M
Slightly volatile
Common Stock Shares Outstanding34.6 M39.6 M30.3 M
Slightly volatile
Liabilities And Stockholders Equity153.6 M255.1 M79 M
Slightly volatile
Non Current Liabilities Total16 M16.9 M90.8 M
Slightly volatile
Other Current Assets4.2 M5.6 M1.6 M
Slightly volatile
Total Liabilities51.3 M29.2 M99.5 M
Slightly volatile
Property Plant And Equipment Gross15.5 M27 M8.8 M
Slightly volatile
Total Current Assets139.5 M231.8 M71.6 M
Slightly volatile
Net Working Capital130.9 M219.4 M64.7 M
Slightly volatile
Property Plant Equipment4.9 M6.2 M4.1 M
Slightly volatile
Current Deferred Revenue3.1 M4.4 M2.3 M
Slightly volatile
Short and Long Term Debt12 K13.5 K14.7 K
Slightly volatile
Short Term Debt3.4 M5.4 M1.1 M
Slightly volatile
Capital Surpluse391.1 M467.5 M327.9 M
Slightly volatile
Non Current Liabilities Other21.6 M20.6 M4.4 M
Slightly volatile

Aura Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM1.3 M683.4 K
Slightly volatile
Interest ExpenseM977.5 K194.7 K
Slightly volatile
Selling General Administrative12.5 M19.8 M7.3 M
Slightly volatile
Other Operating Expenses49.9 M85 M32.9 M
Slightly volatile
Research Development37.5 M65.2 M25.6 M
Slightly volatile
Cost Of RevenueM1.3 M683.4 K
Slightly volatile
Total Operating Expenses49.9 M85 M32.9 M
Slightly volatile
Reconciled DepreciationM1.3 M682.9 K
Slightly volatile
Interest Income7.4 MM1.1 M
Slightly volatile
Selling And Marketing Expenses15.8 M17.8 M19.3 M
Slightly volatile

Aura Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.2 M8.8 M2.2 M
Slightly volatile
Begin Period Cash Flow74.2 M122.4 M36.9 M
Slightly volatile
Other Cashflows From Financing Activities72.3 M94.1 M50.6 M
Slightly volatile
DepreciationM1.3 M683 K
Slightly volatile
Dividends Paid31.8 M35.8 M39 M
Slightly volatile
Capital Expenditures1.1 M709 K1.9 M
Slightly volatile
Issuance Of Capital Stock90 M98.4 M57.1 M
Slightly volatile
Total Cash From Financing Activities90 M97.3 M57.1 M
Slightly volatile
End Period Cash Flow80 M41.9 M49.1 M
Slightly volatile
Change To Netincome7.4 MM1.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.520.54753.2744
Slightly volatile
Payables Turnover0.490.72470.3672
Slightly volatile
Cash Per Share3.015.7082.1219
Slightly volatile
Days Payables Outstanding9685041.4 K
Slightly volatile
Income Quality1.020.83560.8893
Slightly volatile
Net Debt To EBITDA0.240.2571.4018
Very volatile
Current Ratio11.3718.75818.7499
Slightly volatile
Graham Number9.5515.72739.0963
Slightly volatile
Capex Per Share0.0170.01790.062
Slightly volatile
Interest Debt Per Share0.07120.06780.0186
Slightly volatile
Debt To Assets0.01110.01050.0035
Slightly volatile
Days Of Payables Outstanding9685041.4 K
Slightly volatile
Ebt Per Ebit1.070.89740.9978
Pretty Stable
Quick Ratio11.3718.75818.7499
Slightly volatile
Net Income Per E B T1.091.00181.003
Pretty Stable
Cash Ratio3.163.32316.5283
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.161.01111.0909
Slightly volatile
Debt Ratio0.01110.01050.0035
Slightly volatile

Aura Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap362.9 M446.4 M437.2 M
Very volatile
Enterprise Value426.5 M400.1 M395.9 M
Pretty Stable

Aura Fundamental Market Drivers

Cash And Short Term Investments226.2 M

Aura Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aura Biosciences Financial Statements

Aura Biosciences stakeholders use historical fundamental indicators, such as Aura Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Aura Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aura Biosciences' assets and liabilities are reflected in the revenues and expenses on Aura Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aura Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.4 M3.1 M
Cost Of Revenue1.3 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Aura Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aura Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aura Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aura Biosciences Stock:
Check out the analysis of Aura Biosciences Correlation against competitors.
For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.73)
Return On Assets
(0.30)
Return On Equity
(0.51)
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.